{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T08:15:34Z","timestamp":1733645734794,"version":"3.30.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,7]]},"DOI":"10.7759\/cureus.75302","type":"journal-article","created":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T07:48:26Z","timestamp":1733644106000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of Metabolic Dysfunction-Associated Fatty Liver Disease on the Prognosis of Patients With Hepatocellular Carcinoma After Radical Resection: A Retrospective Study"],"prefix":"10.7759","author":[{"given":"Hamza Naseer","family":"Butt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fizza","family":"Arshad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Asad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamza","family":"Wakil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saadia","family":"Zainab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roomisa","family":"Anis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Kirshan Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sana","family":"Sehar Lodhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahwash","family":"Mansoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-024-03385-7","article-title":"Metabolic dysfunction-associated fatty liver disease increases the risk of complications after radical resection in patients with hepatocellular carcinoma","volume":"22","author":"Xiong KG","year":"2024","unstructured":"Xiong KG, Ke KY, Kong JF, Lin TS, Lin QB, Lin S, Zhu YY. Metabolic dysfunction-associated fatty liver disease increases the risk of complications after radical resection in patients with hepatocellular carcinoma. World J Surg Oncol. 2024, 22:117. 10.1186\/s12957-024-03385-7","journal-title":"World J Surg Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S368366","article-title":"Impact of metabolic dysfunction associated fatty liver disease on the prognosis of patients with hepatitis B virus-related hepatocellular carcinoma based on propensity score matching analysis","volume":"14","author":"Xue J","year":"2022","unstructured":"Xue J, Wang QX, Xiao HM, et al.. Impact of metabolic dysfunction associated fatty liver disease on the prognosis of patients with hepatitis B virus-related hepatocellular carcinoma based on propensity score matching analysis. Cancer Manag Res. 2022, 14:2193-202. 10.2147\/CMAR.S368366","journal-title":"Cancer Manag Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.hbpd.2022.04.001","article-title":"The impact of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with hepatocellular carcinoma after radical resection","volume":"22","author":"Xiong KG","year":"2023","unstructured":"Xiong KG, Ke KY, Chen LF, et al.. The impact of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with hepatocellular carcinoma after radical resection. Hepatobiliary Pancreat Dis Int. 2023, 22:366-72. 10.1016\/j.hbpd.2022.04.001","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi Z","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, et al.. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018, 15:11-20. 10.1038\/nrgastro.2017.109","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.07.045","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam M","year":"2020","unstructured":"Eslam M, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020, 73:1575. 10.1016\/j.jhep.2020.07.045","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13565","article-title":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with type 2 diabetes","volume":"35","author":"Sberna AL","year":"2018","unstructured":"Sberna AL, Bouillet B, Rouland A, et al.. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with type 2 diabetes. Diabet Med. 2018, 35:368-75. 10.1111\/dme.13565","journal-title":"Diabet Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2020.01.014","article-title":"Advances in the early diagnosis of hepatocellular carcinoma","volume":"7","author":"Wang W","year":"2020","unstructured":"Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis. 2020, 7:308-19. 10.1016\/j.gendis.2020.01.014","journal-title":"Genes Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14261","article-title":"Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period","volume":"46","author":"Pais R","year":"2017","unstructured":"Pais R, Fartoux L, Goumard C, Scatton O, Wendum D, Rosmorduc O, Ratziu V. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period. Aliment Pharmacol Ther. 2017, 46:856-63. 10.1111\/apt.14261","journal-title":"Aliment Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam M","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020, 158:1999-2014. 10.1053\/j.gastro.2019.11.312","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12742","article-title":"Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study","volume":"125","author":"Rastogi A","year":"2017","unstructured":"Rastogi A, Shasthry SM, Agarwal A, Bihari C, Jain P, Jindal A, Sarin S. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study. APMIS. 2017, 125:962-73. 10.1111\/apm.12742","journal-title":"APMIS"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154955","article-title":"Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers","volume":"127","author":"Liu Z","year":"2022","unstructured":"Liu Z, Lin C, Suo C, Zhao R, Jin L, Zhang T, Chen X. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers. Metabolism. 2022, 127:154955. 10.1016\/j.metabol.2021.154955","journal-title":"Metabolism"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01848-8","article-title":"Associations of six adiposity-related markers with incidence and mortality from 24 cancers-findings from the UK Biobank prospective cohort study","volume":"19","author":"Parra-Soto S","year":"2021","unstructured":"Parra-Soto S, Cowley ES, Rezende LF, et al.. Associations of six adiposity-related markers with incidence and mortality from 24 cancers-findings from the UK Biobank prospective cohort study. BMC Med. 2021, 19:7. 10.1186\/s12916-020-01848-8","journal-title":"BMC Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308139","article-title":"Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours, or portal hypertension","volume":"64","author":"Zhong JH","year":"2015","unstructured":"Zhong JH, Ke Y, Wang YY, Li LQ. Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours, or portal hypertension. Gut. 2015, 64:520-1. 10.1136\/gutjnl-2014-308139","journal-title":"Gut"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07948-9","article-title":"Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods","volume":"21","author":"Kuo MJ","year":"2021","unstructured":"Kuo MJ, Mo LR, Chen CL. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods. BMC Cancer. 2021, 21:250. 10.1186\/s12885-021-07948-9","journal-title":"BMC Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-20-480","article-title":"2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights","volume":"9","author":"Xie DY","year":"2020","unstructured":"Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020, 9:452-63. 10.21037\/hbsn-20-480","journal-title":"Hepatobiliary Surg Nutr"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16563","article-title":"Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma","volume":"54","author":"Harding-Theobald E","year":"2021","unstructured":"Harding-Theobald E, Louissaint J, Maraj B, et al.. Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma. Aliment Pharmacol Ther. 2021, 54:890-901. 10.1111\/apt.16563","journal-title":"Aliment Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy308","article-title":"Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Vogel A","year":"2018","unstructured":"Vogel A, Cervantes A, Chau I, et al.. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018, 29:238-55. 10.1093\/annonc\/mdy308","journal-title":"Ann Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/JCMA.0000000000000530","article-title":"Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease","volume":"84","author":"Lin BZ","year":"2021","unstructured":"Lin BZ, Lin TJ, Lin CL, Liao LY, Chang TA, Lu BJ, Chen KY. Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease. J Chin Med Assoc. 2021, 84:606-13. 10.1097\/JCMA.0000000000000530","journal-title":"J Chin Med Assoc"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study","volume":"63","author":"Piscaglia F","year":"2016","unstructured":"Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, Bellentani S. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016, 63:827-38. 10.1002\/hep.28368","journal-title":"Hepatology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.5009\/gnl18489","article-title":"Novel prognostic nomograms for hepatocellular carcinoma patients with microvascular invasion: experience from a single center","volume":"13","author":"Xu L","year":"2019","unstructured":"Xu L, Li L, Wang P, et al.. Novel prognostic nomograms for hepatocellular carcinoma patients with microvascular invasion: experience from a single center. Gut Liver. 2019, 13:669-82. 10.5009\/gnl18489","journal-title":"Gut Liver"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324915","article-title":"Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database","volume":"72","author":"Vitale A","year":"2023","unstructured":"Vitale A, Svegliati-Baroni G, Ortolani A, et al.. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut. 2023, 72:141-52. 10.1136\/gutjnl-2021-324915","journal-title":"Gut"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.06.024","article-title":"EASL clinical practice guidelines on nutrition in chronic liver disease","volume":"70","author":"Merli M","year":"2019","unstructured":"Merli M, Berzigotti A, Zelber-Sagi S, et al.. EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol. 2019, 70:172-93. 10.1016\/j.jhep.2018.06.024","journal-title":"J Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.783339","article-title":"Outcomes of liver resection for metabolic dysfunction-associated fatty liver disease or chronic hepatitis B-related HCC","volume":"11","author":"Liu L","year":"2021","unstructured":"Liu L, Xie S, Teng YX, et al.. Outcomes of liver resection for metabolic dysfunction-associated fatty liver disease or chronic hepatitis B-related HCC. Front Oncol. 2021, 11:783339. 10.3389\/fonc.2021.783339","journal-title":"Front Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp344","article-title":"Metabolic syndrome and cancer-related mortality among Korean men and women","volume":"21","author":"Lee JS","year":"2010","unstructured":"Lee JS, Cho SI, Park HS. Metabolic syndrome and cancer-related mortality among Korean men and women. Ann Oncol. 2010, 21:640-5. 10.1093\/annonc\/mdp344","journal-title":"Ann Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-018-0398-2","article-title":"Metabolic syndrome is a risk factor for cancer mortality in the general Japanese population: the Jichi Medical School Cohort Study","volume":"11","author":"Watanabe J","year":"2019","unstructured":"Watanabe J, Kakehi E, Kotani K, Kayaba K, Nakamura Y, Ishikawa S. Metabolic syndrome is a risk factor for cancer mortality in the general Japanese population: the Jichi Medical School Cohort Study. Diabetol Metab Syndr. 2019, 11:3. 10.1186\/s13098-018-0398-2","journal-title":"Diabetol Metab Syndr"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100231","article-title":"NAFLD and MAFLD as emerging causes of HCC: a populational study","volume":"3","author":"Myers S","year":"2021","unstructured":"Myers S, Neyroud-Caspar I, Spahr L, et al.. NAFLD and MAFLD as emerging causes of HCC: a populational study. JHEP Rep. 2021, 3:100231. 10.1016\/j.jhepr.2021.100231","journal-title":"JHEP Rep"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/164_2015_12","article-title":"Metabolic syndrome, type 2 diabetes, and cancer: epidemiology and potential mechanisms","volume":"233","author":"Ben-Shmuel S","year":"2016","unstructured":"Ben-Shmuel S, Rostoker R, Scheinman EJ, LeRoith D. Metabolic syndrome, type 2 diabetes, and cancer: epidemiology and potential mechanisms. Handb Exp Pharmacol. 2016, 233:355-72. 10.1007\/164_2015_12","journal-title":"Handb Exp Pharmacol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI21047","article-title":"Splanchnic lipolysis in human obesity","volume":"113","author":"Nielsen S","year":"2004","unstructured":"Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD. Splanchnic lipolysis in human obesity. J Clin Invest. 2004, 113:1582-8. 10.1172\/JCI21047","journal-title":"J Clin Invest"},{"key":"ref31","article-title":"Link between obesity and cancer: role of triglyceride\/free fatty acid cycling","volume":"18","author":"Gong Y","year":"2014","unstructured":"Gong Y, Dou L, Liang J. Link between obesity and cancer: role of triglyceride\/free fatty acid cycling. Eur Rev Med Pharmacol Sci. 2014, 18:2808-20.","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/320543-impact-of-metabolic-dysfunction-associated-fatty-liver-disease-on-the-prognosis-of-patients-with-hepatocellular-carcinoma-after-radical-resection-a-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T07:48:28Z","timestamp":1733644108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/320543-impact-of-metabolic-dysfunction-associated-fatty-liver-disease-on-the-prognosis-of-patients-with-hepatocellular-carcinoma-after-radical-resection-a-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,7]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.75302","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,7]]}}}